Background-The reproducibility of contrast-enhanced MRI has not been established. We compared MRI reproducibility for infarct size determination with that of 99m Tc-sestamibi (MIBI) single photon emission computed tomography (SPECT). Methods and Results-Patients with chronic myocardial infarction defined by enzymes (peak creatine kinase-MB 173Ϯ119 U/L) were scanned twice by MRI (MRI I and MRI II, nϭ20) and twice by SPECT (SPECT I and SPECT II, nϭ15) on the same day. The MRI contrast agent was injected during MRI I but not MRI II to test the effect of imaging time after contrast. Resting Tc-MIBI SPECT images were acquired and infarct size was determined with commercial software. Infarct size in patients scanned by MRI and SPECT was 14Ϯ6% of left ventricular mass (%LV) by MRI (range 4%LV to 27%LV) and 14Ϯ7%LV by SPECT (range 4%LV to 26%LV). MRI I and II scans were performed 10Ϯ2 and 27Ϯ3 minutes after contrast, respectively. For MRI, the difference in infarct size between scans I and II (bias) was Ϫ0.1%LV, and the coefficient of repeatability was Ϯ2.4%LV. For SPECT, bias was Ϫ1.3%LV, and the coefficient of repeatability was Ϯ4.0%LV. Within individual patients, no systematic differences in infarct size were detected when the 2 MRI scans were compared, the 2 SPECT scans were compared, or MRI was compared to SPECT. Conclusion-The size of healed infarcts measured by contrast-enhanced MRI does not change between 10 and 30 minutes after contrast. The clinical reproducibility of contrast-enhanced MRI for infarct size determination compares favorably with that of routine clinical SPECT.
C ontrast-enhanced MRI (ceMRI) is used clinically for the detection and sizing of myocardial infarction at an increasing number of institutions in the United States and Europe. Although there is substantial experimental evidence supporting the use of ceMRI to detect infarction, [1] [2] [3] [4] the reproducibility of ceMRI in a clinical setting has not been established, nor has the utility of this approach been compared with that of single photon emission computed tomography (SPECT) imaging. In particular, no previous studies have addressed the question of how the reproducibility of ceMRI compares with that of 99m Tc-sestamibi (MIBI) SPECT in patients with healed myocardial infarction.
The goal of this study was to establish the clinical reproducibility of ceMRI for the measurement of infarct size. Our study design consisted of 2 consecutive MRI scans (MRI I and II) in patients with documented, healed myocardial infarction. Between MRI scans, the patient was removed from the scanner, and the second MRI scan was performed by a different scanner operator. The MRI contrast agent was injected for MRI I but not for MRI II to address the question of whether infarct size measurement in the setting of chronic myocardial infarction depends on imaging time after contrast injection. 5 To allow the reproducibility of ceMRI to be directly compared with the reproducibility of an existing widely used clinical technique, patients were also scanned twice by resting Tc-MIBI SPECT on the same day as the 2 MRI scans.
Methods

Patient Population
This study was prospectively planned and was approved by the Institutional Review Board of Northwestern University. All patients gave informed consent. Twenty consecutive patients (62Ϯ7 years old) with myocardial infarcts at least 1 year old (3.9Ϯ2.6 years, range 1 to 11 years) who agreed to undergo repeated scans on the same day were enrolled. In all patients, the presence and age of infarction were defined by cardiac enzyme levels (peak creatine kinase [CK] 1934Ϯ1103 U/L, range 327 to 3765; peak CK-MB 173Ϯ119 g/mL, range 39 to 366) at the time of the index event. Figure 1 summarizes the study design. Two MRI scans and 2 SPECT scans were acquired in 15 patients on the same day by different operators after only 1 injection of the MRI contrast agent and 1 injection of MIBI. Five additional patients underwent repeated MRI scans only.
Imaging Protocols
MRI
The methodology for acquiring MR images for the measurement of infarct size has been described in detail elsewhere. 6, 7 In brief, 10 minutes after intravenous injection of an MRI contrast agent (gadoteridol, Bracco Pharmaceuticals, 0.125 mmol/kg), ECG gated shortaxis images were acquired during repeated breath holds every 10 mm from base to apex by an inversion-recovery turbo FLASH (fast, low-angle shot) pulse sequence. 7 After acquisition of the first complete set of contrast images (MRI I), the patient was removed from the scanner and asked to stand up, then was put back in the scanner for the acquisition of the second set of images (MRI II). A different scanner operator, starting from new scout images, acquired images for MRI II. No additional contrast agent was administered between MRI I and MRI II to test the effects of imaging time after contrast.
SPECT
SPECT imaging was performed in all patients on the same day as the MRI procedure (Figure 1 ). Resting 99m Tc sestamibi SPECT images were acquired in the clinical nuclear cardiology laboratory of Northwestern Memorial Hospital with a dual-detector gamma camera (ADAC Vertex), with 64 projections, each for 25 seconds, in a circular 180°orbit. The first set of SPECT images was acquired Ϸ2 hours after isotope injection (SPECT I). The patient was then asked to stand up and to lie down again for a second SPECT scan (SPECT II) performed Ϸ20 minutes after SPECT I.
Determination of Infarct Size
MRI
Infarct size by MRI was determined automatically by computer counting of all hyperenhanced pixels in the myocardium on each of the 6 to 8 short-axis images. Hyperenhanced pixels were defined as those with image intensities Ͼ2 SDs above the mean of image intensities in a remote myocardial region in the same image. Infarct size was determined as a percentage of left ventricular mass (%LV), as the sum of hyperenhanced pixels from each of the 6 to 8 short-axis images divided by the total number of pixels within the LV myocardium multiplied by 100%.
SPECT
Infarct size by SPECT was determined with an automated 3D software package written by investigators at Cedars-Sinai Hospital in Los Angeles, Calif. 8 -10 This program has been tested for reproducibility in 420 patients, 10 and the underlying approach has been systematically compared with the results of expert visual scores. 8 We determined SPECT infarct size as %LV by running a commercial version of this software (QPS Autoquant, ADAC Laboratories) on each of the 30 3D data sets (15 patients times 2 SPECT scans).
Statistical Analysis
Continuous data are expressed as meanϮSD. The reproducibility of MRI and SPECT was analyzed with the repeatability analysis method of Bland-Altman. 11 The agreement between MRI and SPECT (MRI I, MRI II and SPECT I, SPECT II) was analyzed by the agreement using repeated measurements method of BlandAltman. 11 The bias and 95% CIs were calculated as described by Bland-Altman. 11 Results Table 1 summarizes the size of infarction in all patients. In the 15 patients who underwent both MRI and SPECT, infarct size was 14Ϯ6%LV for MRI I and 14Ϯ6%LV for MRI II (14Ϯ6%LV overall). For SPECT, infarct size was 14Ϯ8%LV for SPECT I and 15Ϯ7%LV for SPECT II (14Ϯ7%LV overall). Infarct size for the 5 additional patients who only underwent repeated MRI was 25Ϯ7%LV for MRI I and 25Ϯ8%LV for MRI II. Figure 2 shows a full set of short-axis views of MRI I and MRI II acquired in patient 10. The presence, location, and size of the hyperenhanced region were similar in both MRI scans. The first MRI scan was 9 minutes after contrast, whereas the second scan was 32 minutes after contrast. Figure  3 shows similar results in 6 additional patients. Table 2 summarizes the timing of the 2 MRI scans and the inversion time (TI) for each scan selected by the scanner operators. On average, MRI I was performed 10Ϯ2 minutes after contrast, whereas MRI II was performed 27Ϯ3 minutes after contrast. For every patient, the inversion times selected by the scanner operators were longer for the second MRI scan (average increase 69Ϯ21 ms). The overall inversion times were 316Ϯ20 ms for MRI I and 385Ϯ20 ms for MRI II. Figure 4A shows the results of Bland-Altman repeatability analysis of the MRI data of all 20 patients. The average difference in infarct size between scans I and II (bias) was Ϫ0.1%LV, and the coefficient of repeatability was Ϯ2.4%LV. The 95% CIs for infarct size for comparison of MRI I to MRI II were 2.3%LV and Ϫ2.5%LV, ie, there were no systematic differences in infarct size between the 2 MRI scans. Figure 4B shows the results of Bland-Altman repeatability analysis of the SPECT data. The average difference in infarct size between scans I and II (bias) was Ϫ1.3%LV, and the coefficient of repeatability was Ϯ4.0%LV. The 95% CIs for infarct size for comparison of MRI I to MRI II were 2.7%LV and Ϫ5.3%LV, ie, there were no systematic differences in infarct size between the 2 SPECT scans.
Reproducibility of MRI
Reproducibility of SPECT
Comparison of MRI and SPECT
Bland-Altman analyses of the agreement using repeated measurements of the data (MRI I, MRI II, SPECT I, and SPECT II) revealed that the average difference in infarct size between MRI and SPECT (bias) in the 15 patients who underwent both studies was Ϫ0.5%LV (MRI infarct size smaller than SPECT), and the limit of agreement was Ϯ19.2%LV. The 95% CIs for infarct size for comparison of MRI to SPECT were 18.7%LV and Ϫ19.7%LV, ie, there were no systematic differences in infarct size between MRI and SPECT.
Discussion
The main findings of this study were that the size of healed infarcts as determined by ceMRI does not change between 10 and 30 minutes after contrast injection and that the reproducibility of the MRI measurement compares favorably with that of MIBI SPECT. All values are meanϮSD. Presence, location, and size of hyperenhanced region were similar in both MRI scans. First MRI scan was 9 minutes after contrast, whereas second MR scan was 32 minutes after contrast.
Reproducibility of MRI
We found no differences in infarct size measurement by ceMRI between the MRI scans (eg, Figures 2 through 4) . This finding contradicts the recent findings of Oshinski et al, 5 who reported that infarct size measurement by MRI depends on the timing of imaging after contrast. Specifically, Oshinski et al 5 reported that the spatial extent of hyperenhancement by ceMRI decreased from Ϸ60%LV at 3 minutes after contrast to 30%LV by 40 minutes after contrast. This decrease in the spatial extent of hyperenhancement is Ϸ100-fold greater than the differences in sizes we observed (Figure 4 , biasϭ0.3%LV) for images acquired between 10 and 27 minutes after contrast ( Table 2 ). The discrepancy between the present study and the previous report 5 could be due to differences in imaging times after contrast (3 to 40 minutes compared with 10 and 27 minutes), species (rat versus human), or the time elapsed after infarction (2 days versus Ͼ1 year). As briefly discussed in a recent correspondence, 12 these differences could also relate to details of the MRI technique itself and the pharmacokinetics of the MRI contrast agent. These issues are described in more detail here. Figure 2 , presence, location, and size of hyperenhanced regions in Figure 3 were similar in both MRI scans. 13  11  350  26  390  66  133  153   14  10  330  25  400  64  129  149   15  10  310  24  350  59  123  143   16  11  300  29  380  49  119  139   17  12  340  28  390  ⅐ ⅐ ⅐  ⅐ ⅐ ⅐  ⅐ ⅐ ⅐  18  11  290  30  390  51  122  142   19  11  360  31  430  89  161  181   20  10  330  27  400  44  111  131   All  10Ϯ2  316Ϯ20  27Ϯ3  385Ϯ20  61Ϯ15  128Ϯ16  148Ϯ16 Avg indicates average; Gd, Gadoteridol. All values are meanϮSD.
The primary effect of the MRI contrast agent is to shorten myocardial longitudinal relaxation time, T1, and the underlying physiology results in a situation in which T1 is shortened more in infarcted regions than in normal myocardium. Although these regions of shortened T1 (infarcts) can be visualized with traditional T1-weighted MRI techniques, regional differences in image intensities are greatest when an inversion pulse is used. 6, 7 For correct implementation, however, the inversion time (delay between inversion pulse and data collection) must be manually selected to null signal from normal myocardial regions. The inversion time needed to null signal from normal myocardium varies from patient to patient because of differences in dose and varies with time after contrast administration because of contrast agent pharmokinetics. 6 Weinmann et al 13 studied the pharmacokinetics of Gd-DTPA in humans for doses of 0.1 and 0.25 mmol/kg. The solid line of Figure 5 shows a monoexponential fit to their data interpolated to a dose of 0.125 mmol/kg (the dose used in the present study). The plasma concentration of the MRI contrast agent decreased by a factor of Ϸ2.4 between 3 and 40 minutes after contrast. This decrease in contrast agent concentration will increase myocardial T1 and will require a corresponding increase in the MRI inversion time to appropriately null normal myocardium. Because interstitial concentrations of Gd-DTPA in the myocardium depend primarily on plasma concentrations, the correct MRI inversion time can be estimated from basic physical principles [eg, at 1 minute of 0.125 mmol/kg dose, ⌬1/T1ϭ(0.96 mmol/L)ϫ(4.5/s/mmol/L) ϫ(0.30{extracellular space})ϭ1.29/s; T1ϭ1/(1.29ϩ1/0.8{pre-contrast T1}) ϭ392 ms; inversion time to null normal myocardiumϭ(392)(ln2)ϭ272 ms]. The dashed line in Figure 5 depicts the correct inversion times that are needed for the MRI technique to account for the pharmacokinetics of the MRI contrast agent. The filled circles of Figure 5 show the present data taken from Table 2 . The changes in inversion times selected by the scanner operators of the present study (filled circles) were similar to those expected based on the pharmacokinetics of the contrast agent (dotted line).
MRI Compared With SPECT
The reproducibility of an imaging test has practical implications for the design of clinical trials that use the results of imaging techniques as an end point. Gibbons et al 14 described the influence of measurement reproducibility using SPECT on the number of patients necessary to detect the effects of a candidate intervention as a function of the t statistic. These authors showed that the number of patients needed for a clinical trial is proportional to the square of the SD of the imaging end point. 14 In the present study, the SD of infarct size is one half the coefficient of repeatability, and the ratio of the numbers of patients needed for clinical trials based on MRI compared with SPECT is 0.42 [(2.6/4.0) 2 ϭ0.42]. Accordingly, if no other factors play a role, MRI reduces the number of patients needed for a clinical trial to 42% of that needed if infarct size is determined by SPECT. However, this estimate is based on a limited number of patients and does not address the important issue of accuracy, because the true infarct size is not known.
Conclusion
In summary, we found that the size of healed infarcts measured by ceMRI does not change between 10 and 30 minutes after contrast and that the reproducibility of ceMRI compares favorably with that of 99m Tc sestamibi SPECT. Table 2 . See text for details.
